Published January 12, 2011 | Version v1
Journal article

Can Bcl-XL expression predict the radio sensitivity of Bilharzial-related squamous bladder carcinoma? a prospective comparative study

  • 1. Urology Department, Assiut University Hospital, Assiut (Egypt)
  • 2. Urology Department, Faculty of medicine, Assiut University, Assiut (Egypt)
  • 3. Immunohistochemistry Laboratory, Clinical Pathology Department, South Egypt Cancer Institute, Assiut University, Assiut (Egypt)
  • 4. Radiotherapy Department, South Egypt Cancer Institute, Assiut University, Assiut (Egypt)
  • 5. Pathology Department, Faculty of Medicine, Assiut University, Assiut (Egypt)
  • 6. Public Health Department, Faculty of Medicine, Assiut University, Assiut (Egypt)

Description

Local pelvic recurrence after radical cystectomy for muscle invasive bilharzial related squamous cell carcinoma accounts for 75% of treatment failures even in organ confined tumors. Despite the proven value of lymphadenectomy, up to 60% of patients undergoing cystectomy do not have it. These factors are in favor of adjuvant radiotherapy reevaluation. objectives: to evaluate the effect of adjuvant radiotherapy on disease free survival in muscle invasive bilharzial related squamous cell carcinoma of the urinary bladder and to test the predictability of radio-sensitivity using the anti apoptotic protein Bcl-XL. The study prospectively included 71 patients, (47 males, 24 females) with muscle invasive bilharzial related squamous cell carcinoma of the bladder (Stage pT2a-T3N0-N3M0) who underwent radical cystectomy in Assiut university hospitals between January 2005 and December 2006. Thirty eight patients received adjuvant radiotherapy to the pelvis in the dose of 50Gy/25 fractions/5 weeks (Group 1), while 33 patients did not receive adjuvant radiotherapy (group 2). Immunohistochemical characterization for bcl-xL expression was done. Follow up was done every 3 months for 12 to 36 months with a mean of 16 ± 10 months. All data were analyzed using SPSS version 16. Three years cumulative disease free survival was calculated and adjusted to Bcl-XL expression and side effects of the treatment were recorded. The disease free cumulative survival was 48% for group 1 and 29% for group 2 (log rank p value 0.03). The multivariate predictors of tumor recurrence were the positive Bcl-XL expression (odd ratio 41.1, 95% CI 8.4 - 102.3, p < 0.0001) and radiotherapy (odd ratio 0.19, 95% CI 0.05 - 0.78, p < 0.02). With Cox regression, the only independent multivariate predictor of radio-sensitivity was the Bcl-XL expression with odd ratio 4.6 and a p value < 0.0001. All patients tolerated the treatment with no life threatening or late complications during the period of follow up. Adjuvant radiotherapy for muscle invasive bilharzial related squamous cell carcinoma of the urinary bladder has potential effectiveness and minor side effects. Moreover, Bcl-XL expression is a valuable tool for predicting those who might not respond to this adjuvant treatment

Availability note (English)

Available from http://dx.doi.org/10.1186/1471-2407-11-16; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033850

Additional details

Publishing Information

Journal Title
BMC cancer (Online)
Journal Volume
11
Journal Page Range
p. 16
ISSN
1471-2407

INIS

Country of Publication
United Kingdom
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
46098813
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
BLADDER; CARCINOMAS; DOSES; EDUCATIONAL FACILITIES; FAILURES; HOSPITALS; MALES; MUSCLES; PATIENTS; PELVIS; PROTEINS; RADIOTHERAPY; SENSITIVITY; SIDE EFFECTS
Descriptors DEC
BODY; BUILDINGS; DISEASES; MEDICAL ESTABLISHMENTS; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; ORGANIC COMPOUNDS; ORGANS; RADIOLOGY; THERAPY; URINARY TRACT

Optional Information

Copyright
Copyright (c)2011 Abdel Raheem et al
Notes
PMCID: PMC3033850; PUBLISHER-ID: 1471-2407-11-16; PMID: 21226954; OAI: oai:pubmedcentral.nih.gov:3033850; licensee BioMed Central Ltd.